M&G PLC Grows Position in Amgen Inc. $AMGN

M&G PLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 454,584 shares of the medical research company’s stock after purchasing an additional 16,646 shares during the period. M&G PLC owned approximately 0.08% of Amgen worth $128,193,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Laurel Wealth Advisors LLC raised its position in shares of Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after buying an additional 6,676,575 shares during the period. Norges Bank acquired a new stake in Amgen during the second quarter worth about $1,663,726,000. Vanguard Group Inc. raised its holdings in shares of Amgen by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock worth $14,996,807,000 after purchasing an additional 841,117 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Amgen by 5.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after purchasing an additional 687,735 shares in the last quarter. Finally, Mizuho Markets Cayman LP purchased a new stake in shares of Amgen during the 2nd quarter worth about $135,597,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 0.8%

Shares of NASDAQ AMGN opened at $369.19 on Monday. The firm has a market cap of $198.80 billion, a price-to-earnings ratio of 25.94, a PEG ratio of 3.78 and a beta of 0.46. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $385.12. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock’s 50-day simple moving average is $337.47 and its 200-day simple moving average is $313.77.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the firm earned $5.31 EPS. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s payout ratio is presently 70.84%.

Analyst Ratings Changes

Several research firms recently commented on AMGN. Argus raised their price target on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a report on Friday, February 6th. Daiwa Securities Group lifted their target price on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Leerink Partners raised their price objective on Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Finally, Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $354.04.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.69% of the stock is owned by corporate insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: European Commission approval for Uplinza (amifampridine) for generalized myasthenia gravis expands Amgen’s labelled indications in Europe and supports incremental near-term revenue potential for the product. Amgen wins EC approval for Uplinza in gMG
• Positive Sentiment: Amgen announced an increase to its dividend to $2.52, which boosts yield and signals management confidence in cash flow — typically supportive for a large-cap, dividend-oriented stock. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
• Positive Sentiment: Unusually large call-option activity (roughly 320,232 calls bought) points to short-term bullish positioning by some investors, which can amplify upside moves in the stock. (No source link provided in feed)
• Neutral Sentiment: Amgen will present at Citi’s 2026 Virtual Oncology Leadership Summit — a standard investor relations event that raises visibility on oncology programs but is not intrinsically catalytic. AMGEN TO PRESENT AT CITI’S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
• Neutral Sentiment: Analyst notes are mixed: Argus reiterated a Buy with a $400 target while Guggenheim reaffirmed a Hold — this provides conflicting signals but keeps the stock in analysts’ focus. Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Industry coverage (CNBC) on pharma’s resetting priorities — pricing, pipelines and patent cliffs — is a sector-level backdrop that could affect sentiment for large-cap drugmakers like Amgen but is not company-specific. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Recent entries on short interest in the data feed appear to be reporting zero shares / NaN changes (likely a reporting glitch) and do not signal a meaningful rise in short positioning. (No link provided)

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.